FDA Approved Products

6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
DIGOXIN
digoxin
LOE Approaching
HikmaHikma
ORAL · ELIXIR
mild to moderate heart failureheart failure+1
2004
NDA
60/100
FLOVENT DISKUS 100
fluticasone propionate
LOE Approaching
GSKGSK
INHALATION · POWDER
asthma
2000
NDA
60/100
VYVANSE
lisdexamfetamine dimesylate
LOE Approaching
TakedaTakeda
ORAL · CAPSULE
(): Attention Deficit Hyperactivity Disorder (ADHD) in adultsa higher incidence of adverse reactions (e
2007
NDA
60/100
VYVANSE
lisdexamfetamine dimesylate
Peak
TakedaTakeda
ORAL · TABLET, CHEWABLE
(): Attention Deficit Hyperactivity Disorder (ADHD) in adultsa higher incidence of adverse reactions (e
2017
NDA
60/100
FLOVENT HFA
fluticasone propionate
LOE Approaching
GSKGSK
INHALATION · AEROSOL, METERED
asthma
2004
NDA
55/100
AFINITOR DISPERZ
everolimus
Peak
NovartisNovartis
ORAL · TABLET, FOR SUSPENSION
older with TSCpostmenopausal women with advanced hormone receptor-positive+13
2012
NDA
45/100
CIPRO
ciprofloxacin
LOE Approaching
BayerBayer
ORAL · FOR SUSPENSION
plagueincluding pneumonic+38
1997
SMNDA
45/100
ELOXATIN
oxaliplatin
LOE Approaching
SanofiSanofi
INTRAVENOUS · INJECTABLE
colorectal cancer
2005
NDA
45/100
HYDROMORPHONE HYDROCHLORIDE
hydromorphone hydrochloride
Growth
HikmaHikma
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · SOLUTION
pain severe enough to require an opioid analgesicfor which alternate treatments are inadequate
2023
NDA
45/100
INFUMORPH
morphine sulfate
LOE Approaching
HikmaHikma
INJECTION · INJECTABLE
1984
NDA
45/100
LITHIUM CARBONATE
lithium carbonate
LOE Approaching
HikmaHikma
ORAL · CAPSULE
acute manicmixed episodes in patients 7 years+1
1980
NDA
45/100
LITHIUM CARBONATE
lithium carbonate
LOE Approaching
HikmaHikma
ORAL · TABLET
acute manicmixed episodes in patients 7 years+1
1982
NDA
45/100
MENOSTAR
estradiol
LOE Approaching
BayerBayer
TRANSDERMAL · FILM, EXTENDED RELEASE
1994
NDA
45/100
MYCAMINE
micafungin sodium
LOE Approaching
AstellasAstellas
INTRAVENOUS · INJECTABLE
Acute Disseminated CandidiasisAbscesses in adult+4
2005
NDA
45/100
REGONOL
pyridostigmine bromide
LOE Approaching
NovartisNovartis
INJECTION · INJECTABLE
1973
NDA
45/100
TAMIFLU
oseltamivir phosphate
LOE Approaching
RocheRoche
ORAL · FOR SUSPENSION
acuteuncomplicated illness due to influenza A+4
2000
NDA
45/100
TAMIFLU
oseltamivir phosphate
LOE Approaching
RocheRoche
ORAL · CAPSULE
acuteuncomplicated illness due to influenza A+4
1999
NDA
45/100
VAGIFEM
estradiol
LOE Approaching
Novo NordiskNovo Nordisk
VAGINAL · TABLET
1999
NDA
45/100
VENTOLIN HFA
albuterol sulfate
LOE Approaching
GSKGSK
INHALATION · AEROSOL, METERED
exercise-induced bronchospasm in adultolder
2001
NDA
45/100
ZORTRESS
everolimus
LOE Approaching
NovartisNovartis
ORAL · TABLET
2010
NDA
45/100
ZYTIGA
abiraterone acetate
LOE Approaching
J&
Johnson & Johnson
ORAL · TABLET
combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC)prostate cancer
2011
NDA
45/100
PROGRAF
tacrolimus
LOE Approaching
AstellasAstellas
INJECTION · INJECTABLE
organ rejection in adultkidney+4
1994
NDA
40/100
PROGRAF
tacrolimus
Peak
AstellasAstellas
ORAL · FOR SUSPENSION
organ rejection in adultkidney+4
2018
NDA
40/100
PROGRAF
tacrolimus
LOE Approaching
AstellasAstellas
ORAL · CAPSULE
organ rejection in adultkidney+4
1994
NDA
40/100
Page 1 of 277Next →